Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012203
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Heidelberg Pharma AG(Heidelberg Pharma) formerly known as Wilex AG is a biopharmaceutical company with a focus on cancer. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. It develops products based on and small molecules and antibodies, which are offered for out-licensing. Wilex’s pipeline products are focused at treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Heidelberg Pharma GmbH (Heidelberg), Wilex’s subsidiary provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg focuses on the development of a proprietary ADC technology. Heidelberg Pharma is headquartered in Munich, Germany.

Heidelberg Pharma AG (WL6) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Licensing Agreements 18
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Equity Offering 23
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Debt Offering 33
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
Asset Transactions 34
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
Acquisition 35
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG – Key Competitors 37
Heidelberg Pharma AG – Key Employees 38
Heidelberg Pharma AG – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Jul 13, 2017: WILEX reports on first half-year 40
Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 42
Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 44
Jul 14, 2016: WILEX publishes Half-yearly Financial Report 46
Apr 14, 2016: WILEX AG: Interim management statement on the first quarter of 2016 48
Mar 22, 2016: WILEX announces financial figures for the 2015 financial year and reports on course of business 51
Corporate Communications 53
Jun 02, 2016: WILEX announces change on the Executive Management Board 53
Apr 06, 2016: WILEX plans change on the Supervisory Board 54
Product News 55
03/01/2016: RedHill Biopharma Provides Update on MESUPRON 55
Product Approvals 56
Jan 13, 2016: WILEX’s partner Link Health submits IND application for clinical Phase I with the uPA inhibitor MESUPRON in China 56
Other Significant Developments 57
Oct 13, 2016: WILEX: Interim Management Statement on the First Nine Months of 2016 57
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Heidelberg Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Telix Pharma Enters into Licensing Agreement with Wilex 12
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 13
Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 14
Heidelberg Pharma Enters into Agreement with Celonic 15
Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 16
MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 17
Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 18
RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 19
Wilex Enters Into Licensing Agreement With Link Health For Mesupron 20
Heidelberg Pharma Enters Into Licensing Agreement With Roche For Antibody Targeted Amanitin Conjugates 21
WILEX Enters Into Licensing Agreement With Prometheus Labs For RENCAREX 22
Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 23
Wilex Raises USD5.4 Million in Rights Offering of Shares 24
Wilex to Raise USD4.7 Million in Rights Offering of Shares 25
Wilex Raises USD1.81 Million in Private Placement of Shares 27
Wilex Raises USD0.86 Million in Rights Offering of Shares 28
Wilex Raises USD4.4 Million in Right Issue of Shares 29
Wilex Completes Private Placement Of Shares For US$12.4 Million 30
Wilex Completes Rights Offering Of Shares For US$7.8 Million 31
Wilex Completes Rights Offering Of Shares For US$12.6 Million 32
Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33
UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34
WILEX Acquires Heidelberg Pharma For US$26.8 Million 35
Heidelberg Pharma AG, Key Competitors 37
Heidelberg Pharma AG, Key Employees 38
Heidelberg Pharma AG, Subsidiaries 39

★海外企業調査レポート[Heidelberg Pharma AG (WL6)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Weifa AS-製薬・医療分野:企業M&A・提携分析
    Summary Weifa AS (Weifa), a subsidiary of Weifa ASA, is a healthcare solution provider that research, develops, produces, distributes and sells medicines, and lifestyle products. The company’s products comprise Tylenol, paracetduo, ibux, ibux gel, tiger balm, proxan, nazareth, dexyl, tussin, bronkyl …
  • SK Chemicals Co Ltd (006120):企業の財務・戦略的SWOT分析
    Summary SK Chemicals Co Ltd (SK Chemicals) is a provider of chemical and pharmaceutical products. The company offers pharmaceutical drugs to treat erectile dysfunction, arthritis, peptic ulcer, gastroesophageal reflux disease (GERD), cancer and to improve blood circulation. It manufactures green che …
  • Canon Marketing Japan Inc (8060):企業の財務・戦略的SWOT分析
    Canon Marketing Japan Inc (8060) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Andhra Bank (ANDHRABANK):企業の財務・戦略的SWOT分析
    Andhra Bank (ANDHRABANK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Forward Industries, Inc. (FORD):企業の財務・戦略的SWOT分析
    Forward Industries, Inc. (FORD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Consolidated Edison Company of New York, Inc.:発電所・企業SWOT分析
    Consolidated Edison Company of New York, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, in …
  • Alfa Laval AB (ALFA):企業の財務・戦略的SWOT分析
    Alfa Laval AB (ALFA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Voyager Therapeutics Inc (VYGR):企業の財務・戦略的SWOT分析
    Summary Voyager Therapeutics Inc (Voyager) is a clinical-stage gene therapy company that develops treatments for patients suffering from severe neurological diseases. The company provides treatment for adeno-associated virus gene therapy field by selecting, designing and manufacturing vectors. Its c …
  • Credit Suisse Group AG:戦略・SWOT・企業財務分析
    Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Relmada Therapeutics Inc (RLMDD):企業の財務・戦略的SWOT分析
    Summary Relmada Therapeutics Inc (Relmada Therapeutics), formerly Camp Nine Inc, is a pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s product pipeline includes REL-1017 d-Methadone, an antagonist for the treat …
  • The Boston Consulting Group:企業の戦略・SWOT・財務情報
    The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report Summary The Boston Consulting Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • ArmaGen Inc-製薬・医療分野:企業M&A・提携分析
    Summary ArmaGen Inc (ArmaGen), formerly ArmaGen Technologies Inc is a healthcare solution provide that discovers and develops novel therapies for the treatment of neurological disorders. The company's pipeline portfolio includes AGT-181, AGT-182, AGT-183 and AGT-184 which are used for the treatment …
  • Net One Systems Co Ltd (7518):企業の財務・戦略的SWOT分析
    Net One Systems Co Ltd (7518) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Trane Technologies Plc (TT):企業の財務・戦略的SWOT分析
    Trane Technologies Plc (TT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Assertio Therapeutics Inc:企業の戦略・SWOT・財務分析
    Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report Summary Assertio Therapeutics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mitsubishi Estate Co., Ltd. (8802):企業の財務・戦略的SWOT分析
    Mitsubishi Estate Co., Ltd. (8802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Amadeus IT Group S.A.:企業の戦略・SWOT・財務情報
    Amadeus IT Group S.A. - Strategy, SWOT and Corporate Finance Report Summary Amadeus IT Group S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hokkaido Electric Power Co Inc:発電所・企業SWOT分析
    Hokkaido Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on ke …
  • Luminex Corp (LMNX)-製薬・医療分野:企業M&A・提携分析
    Summary Luminex Corp (Luminex) is a medical devices company which develops, manufactures and markets proprietary biological testing technologies. The company offers wide range of products including instruments, assays, reagents and accessories, software and replacement parts. Its proprietary technol …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆